Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

Fig. 3

7-point SMBG levels at baseline and week 24. Mean unadjusted 7-point SMBG levels at baseline and week 24 in Latin American participants with type 2 diabetes mellitus who were treated with LM25 or IGL for 24 weeks. Error bars indicate standard deviation. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SMBG self-monitoring of blood glucose

Back to article page